CoChat

PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer

Open access

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Background: Using comprehensive plasma lipidomic profiling from men with metastatic castration-resistant prostate cancer (mCRPC), we have previously identified a poor-prognostic lipid profile associated with shorter overall survival (OS). In order to translate this biomarker into the clinic, these men must be identifiable via a clinically accessible, regulatory-compliant assay. Methods: A single regulatory-compliant liquid chromatography-mass spectrometry assay of candidate lipids was developed and tested on a mCRPC Discovery cohort of 105 men. Various risk-score Cox regression prognostic models of OS were built using the Discovery cohort. The model with the highest concordance index (PCPro) was chosen for validation and tested on an independent Validation cohort of 183 men. Results: PCPro, the lipid biomarker, contains Cer(d18:1/18:0), Cer(d18:1/24:0), Cer(d18:1/24:1), triglycerides and total cholesterol. Within the Discovery and Validation cohorts, men who were PCPro positive had significantly shorter OS compared to those who were PCPro negative (Discovery: median OS 12.0 months vs 24.2 months, hazard ratio (HR) 3.75 [95% confidence interval (CI) 2.29–6.15], p < 0.001, Validation: median OS 13.0 months vs 25.7 months, HR = 2.13 [95% CI 1.46–3.12], p < 0.001). Conclusions: We have developed PCPro, a lipid biomarker assay capable of prospectively identifying men with mCRPC with a poor prognosis. Prospective clinical trials are required to determine if men who are PCPro positive will benefit from therapeutic agents targeting lipid metabolism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41391-023-00666-2

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Patient cohorts and analysis strategy. mCRPC metastatic castration-resistant prostate cancer, LC-MS Liquid Chromatography-Mass Spectrometry, LASSO least absolute shrinkage and selection operator.
Fig. 1 Patient cohorts and analysis strategy. mCRPC metastatic castration-resistant prostate cancer, LC-MS Liquid Chromatography-Mass Spectrometry, LASSO least absolute shrinkage and selection operator.CC BY · PubMed Central
Fig. 2 Kaplan-Meier survival analysis of overall survival by PCPro in the Discovery and Validation cohorts. A Survival in the Discovery cohort, B Survival in the Validation cohort, C Survival in those treated with ARSI in the Validation cohort, D Survival in those treated with taxane chemotherapy in the Validation cohort, E Survival in those treated with first line treatment in the Validation cohort, and F Survival in those treated with second line treatment in the Validation cohort. ARSI androgen receptor signalling inhibitor, HR hazard ratio, mo months, OS overall survival.
Fig. 2 Kaplan-Meier survival analysis of overall survival by PCPro in the Discovery and Validation cohorts. A Survival in the Discovery cohort, B Survival in the Validation cohort, C Survival in those treated with ARSI in the Validation cohort, D Survival in those treated with taxane chemotherapy in the Validation cohort, E Survival in those treated with first line treatment in the Validation cohort, and F Survival in those treated with second line treatment in the Validation cohort. ARSI androgen receptor signalling inhibitor, HR hazard ratio, mo months, OS overall survival.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. National Pathology Accreditation Advisory Council. Requirements for the Development and Use of In-House In Vitro Diagnostic Medical Devices (IVDs) (Fourth Edition 2018). Fourth ed. Australia: National Pathology Accreditation Advisory Council; 2018.

Cited by

See all 17

Metadata

Authors
Scheinberg, T., Lin, H.-M., Fitzpatrick, M., Azad, A. A., Bonnitcha, P., Davies, A., Heller, G., Huynh, K., Mak, B., Mahon, K., Sullivan, D., Meikle, P. J., & Horvath, L. G.
Affiliations
  • The University of Sydney (AU)
  • Garvan Institute of Medical Research (AU)
  • Royal Prince Alfred Hospital (AU)
  • The University of Melbourne (AU)
  • Monash Health (AU)
  • Baker Heart and Diabetes Institute (AU)
Corresponding author
Horvath, Lisa G.
Venue
Prostate Cancer and Prostatic Diseases
Published
2023-05-05
Volume
27
Issue
1
Pages
136-143
ISSN
  • 1365-7852 (ISSN-L)
  • 1476-5608
OpenAlex
W4372270897
Cited by
15
References
29
Citations by year
2026: 6 · 2025: 4 · 2024: 4 · 2023: 1
FWCI
1.91
Type
journal article
Language
en
Open access
Licence
Locations
  • Prostate Cancer and Prostatic Diseases (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
  • Prostate Cancer Foundation
  • Movember Foundation (MRTA-3)
  • Australian Prostate Cancer Research
  • Australian Government
  • Prostate Cancer Foundation of Australia (MRTA3)
  • Cancer Institute NSW (10/TPG/1‐04, 2018/TPG001, 10/TPG/1-04, 2018/TPG001)
  • State Government of Victoria
  • Astellas Pharma
  • Australian and New Zealand Urogenital and Prostate Cancer Trials Group
  • Medical Research Council
  • National Health and Medical Research Council (2009965, 1197190, 1196225, 1098647)
  • Cancer Council NSW (PG 10-01)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
Keywords
metastatic castration-resistant prostate cancer, plasma lipidomics, prognostic factors, overall survival, ceramide, triglycerides, cholesterol, lipid metabolism
MeSH terms
Humans, Lipids, Male, Prognosis, Prospective Studies, Biomarkers, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer. https://app.cochat.ai/papers/10.1038/s41391-023-00666-2
The paper
Scheinberg, T., Lin, H.-M., Fitzpatrick, M., Azad, A. A., Bonnitcha, P., Davies, A., Heller, G., Huynh, K., Mak, B., Mahon, K., Sullivan, D., Meikle, P. J., & Horvath, L. G. (2024). PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-023-00666-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.